Vor Biopharma Inc
NASDAQ:VOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beijing Science Sun Pharmaceutical Co Ltd
SZSE:300485
|
CN |
|
Daifuku Co Ltd
TSE:6383
|
JP |
|
P
|
Pierre et Vacances SA
LSE:0OQ0
|
FR |
|
S
|
Shenzhen Dynanonic Co Ltd
SZSE:300769
|
CN |
|
Carvana Co
NYSE:CVNA
|
US |
Vor Biopharma Inc
Total Current Liabilities
Vor Biopharma Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vor Biopharma Inc
NASDAQ:VOR
|
Total Current Liabilities
$25.2m
|
CAGR 3-Years
24%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Vor Biopharma Inc
Glance View
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 135 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. VOR33 is the lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. The company is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML. The company offers VCAR33 programs that are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33.
See Also
What is Vor Biopharma Inc's Total Current Liabilities?
Total Current Liabilities
25.2m
USD
Based on the financial report for Dec 31, 2025, Vor Biopharma Inc's Total Current Liabilities amounts to 25.2m USD.
What is Vor Biopharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
20%
Over the last year, the Total Current Liabilities growth was 35%. The average annual Total Current Liabilities growth rates for Vor Biopharma Inc have been 24% over the past three years , 20% over the past five years .
